Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

"Entering a Clinical Trial: Is it Right for You?": a randomized study of The Clinical Trials Video and its impact on the informed consent process.

Hoffner B, Bauer-Wu S, Hitchcock-Bryan S, Powell M, Wolanski A, Joffe S.

Cancer. 2012 Apr 1;118(7):1877-83. doi: 10.1002/cncr.26438. Epub 2011 Aug 25.

2.

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM.

Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14.

3.

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE.

N Engl J Med. 1986 Sep 11;315(11):657-63.

PMID:
2943992
4.

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia.

Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE.

Med Pediatr Oncol. 1986;14(4):211-5.

PMID:
3462467
5.

Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia.

Niemeyer CM, Hitchcock-Bryan S, Sallan SE.

Semin Oncol. 1985 Jun;12(2):122-30. No abstract available.

PMID:
3859923
6.

Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.

Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E 3rd, Nathan DG.

Cancer Res. 1983 Nov;43(11):5601-7.

7.

Supplemental Content

Loading ...
Support Center